The Buffett Bull Case For GlaxoSmithKline plc

A Warren Buffett fan considers the investment case for GlaxoSmithKline plc (LON:GSK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Many investors who focus on a low price-to-earnings (P/E) ratio and high dividend yield in their search for value will have a hard time swallowing the maxim legendary investor Warren Buffett lives by: “It’s far better to buy a wonderful company at a fair price than a fair company at a wonderful price”.

Today, I’m considering whether FTSE 100 pharmaceuticals giant GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) is a ‘wonderful’ company, and whether its shares are trading at a ‘fair’ price.

A wonderful company?

Buffett’s investment company, Berkshire Hathaway (NYSE: BRK-B.US), actually has a small stake in GlaxoSmithKline — first disclosed during February 2008. Interestingly, Berkshire invested at a time when GSK’s chief executive, Jean-Pierre Garnier, was retiring and being replaced by Andrew Witty.

Buffett is well known for his admiration of long-tenured managers with a passion and commitment to their companies. While Witty was new to the chief executive role, he’d been with GSK since 1985, gaining extensive experience across the business, latterly as president of GSK Europe. Witty is now in his sixth year as chief executive, and at just 49 years old could have a long tenure ahead.

If Witty fits the character profile of a Buffett manager, the numbers he’s producing at GSK also stack up. Buffett is dismissive of companies trumpeting “record earnings per share”. He says: “We believe a more appropriate measure of managerial economic performance to be return on equity capital”.

Wonderful companies deliver a high return on equity (ROE). Let’s pitch GSK’s percentage ROE over the period of Witty’s tenure against that of the UK’s no. 2 drugs company, AstraZeneca, which Berkshire doesn’t hold.

Company 2008 2009 2010 2011 2012 Average
GlaxoSmithKline 43.2 39.5 23.3 38.4 42.8 37.4
AstraZeneca 33.9 31.9 31.9 34.2 25.6 31.5

Source: Morningstar

Now, GSK’s ROE has been enhanced by higher borrowings than AstraZeneca, but it’s actually made sense for strong companies to borrow at the attractive rates on offer in recent years. Buffett doesn’t mind a manageable level of debt, and GSK’s interest cover ratio on its borrowings is a healthy 10.

A fair price?

Berkshire actually trimmed its stake in GSK by a small amount during the second quarter of this year. I can’t tell you the price the sale was made at, but GSK’s average closing price during the period was 1,655p (low 1,517p; high 1,778p). GSK’s current share price is 1,603p, so within a range where Berkshire has sold a few shares, held the vast majority, but not been tempted to buy more.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> G A Chester does not own any shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »